Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Endovascular Journal. 2008; 1 (2): 78-88
en Inglés | IMEMR | ID: emr-86445

RESUMEN

After myocardial infarction, injured cardiomyocytes are replaced by fibrotic tissue promoting the development of heart failure. Stem cells are multipotent, undifferentiated cells capable of multiplication and differentiation. Preliminary experimental evidence suggests that stem cells derived from embryonic or adult tissues [especially bone marrow] may develop into myocardial cells. The overall clinical experience also suggests that stem cell therapy can be safely performed, if the right cell type is used in the right clinical setting. Preliminary efficacy data indicate that stem cells have the potential to enhance myocardial perfusion and/or contractile performance in patients with acute myocardial infarction, advanced coronary artery disease, and chronic heart failure. However, at the present time, the results have been mixed and inconclusive, and the mechanism of stem cell transplantation therapy remains unclear. This review discusses the controversies and problems that need to be addressed in future investigations


Asunto(s)
Humanos , Células Madre Embrionarias , Células Madre , Células Madre Hematopoyéticas , Células Madre Mesenquimatosas , Antígenos CD , Infarto del Miocardio , Isquemia Miocárdica , Insuficiencia Cardíaca , Cardiomiopatías
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA